trending Market Intelligence /marketintelligence/en/news-insights/trending/EvsT_aM3CkXC4VS1B9TfpA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Life Sciences Partners fetches more than €750M across 3 vehicles

Street Talk Episode 68 - As many investors zig away from bank stocks, 2 vets in the space zag toward them

Street Talk Episode 66 - Community banks tap the debt markets while the getting is good

Street Talk Episode 67 - Veteran investor tabs Mick Mulvaney to help with latest financial stock-focused fund

Street Talk Episode 65 - Deferral practices trap US bank portfolios in purgatory


Life Sciences Partners fetches more than €750M across 3 vehicles

Dutch investment firm Life Sciences Partners BV, or LSP, corralled more than €750 million in capital commitments across three investment vehicles.

The fundraising took 10 months, and the proceeds will be used to finance European drug-development and medical-technology companies.

New and existing investors include blue-chip insurance companies, pension funds, government funds, asset managers, family offices and big pharmaceutical enterprises.

The life sciences- and healthcare-focused funds consist of LSP 6, LSP Health Economics Fund 2 and LSP Life Sciences Fund.

LSP 6 will target early- to late-stage drug- and technology-development companies. It has collected over €410 million of capital and is still open for commitments.

LSP Health Economics Fund 2 will focus on late-stage medical-technology companies and secured €280 million of capital in its final close in December 2017.

LSP Life Sciences Fund will invest in publicly listed small- to mid-cap healthcare companies. It has raised about €200 million of capital, together with several related funds.